MEDI5752 in Japanese Patients With Advanced Solid Tumors.

Advanced Solid Tumors Clinical Trial

Official title:

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Japanese Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05685472
• Other study ID #: D7980C00006
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: December 8, 2022
• Est. completion date: March 11, 2024

Study information

• Verified date: February 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label study evaluate the safety, tolerability, pharmacokinetics, immunogenicity and anti-tumor activity of MEDI5752 in Japanese patients with advanced solid solid tumors.

Description:

Primary Objective: To evaluate the safety and tolerability of MEDI5752 in Japanese subjects with advanced solid tumors. Secondary Objective: To assess the anti-tumor activity and efficacy of MEDI5752. To describe the pharmacokinetics of MEDI5752. Exploratory Objective: To conduct exploratory research into factors that may be predictive of response or may influence the progression of cancer and/or response (efficacy) to MEDI5752. Eligible patients will be administered as a single dose at each Cycle Day1. Each cycle from Cycle 1 has a duration of 21 days. A minimum of 3 and a maximum of 9 evaluable patients will be enrolled in each cohort.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 6
• Est. completion date: March 11, 2024
• Est. primary completion date: August 8, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Criteria

1. Age = 18 years at the time of screening

2. World Health Organization/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment

3. Life expectancy = 12 weeks

4. Histologically or cytologically-confirmed advanced solid tumors

5. Subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy or any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment may be eligible to enter the study following a washout period as applicable

6. Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception

7. Nonsterilized males who are sexually active with a female partner of childbearing potential must use a male condom from Day 1 and for 90 days after the final dose of investigational product.

8. Subjects must have at least one measurable lesion

9. Adequate organ and marrow function

10. Signed and dated written informed consent

11. Subjects must provide tumor material as applicable Exclusion Criteria

1. Involvement in the planning and/or conduct of the study (applies to both sponsor staff and/or staff at the study site)

2. Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional study

3. For subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4:

1. Subjects must not have received anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 21 days of commencing treatment with investigational product.

2. Subject must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.

3. All AEs while receiving prior immunotherapy must have completely resolved or resolved to Grade 1 prior to screening for this study.

4. Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product is excluded.

5. Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational product.

6. Active or prior documented autoimmune or inflammatory disorders

7. History of organ transplant

8. Known allergy or reaction to any component of the planned study treatment.

9. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression

10. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria

11. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of Investigational Product or still recovering from prior surgery

12. Female subjects who are pregnant or breastfeeding, as well as male or female subjects of reproductive potential who are not willing to employ one highly effective method of birth control

13. Uncontrolled intercurrent illness, that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the subject to give written informed consent.

14. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of the subject's safety or study results

15. Judgment by the investigator that the subject is unsuitable to participate in the study and the subject is unlikely to comply with study procedures, restrictions, and requirements.

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Neoplasms

Intervention

Biological:
• MEDI5752
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.

Locations

Country	Name	City	State
Japan	Research Site	Chuo-ku
Japan	Research Site	Kashiwa

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of subjects experiencing treatment related adverse events (AEs)	The primary endpoint is as assessed by the number of subjects experiencing adverse events (AEs) graded per NCI CTCAE v5.0.	From the time of informed consent through 90 days following termination of treatment with investigational product
Primary	The number of subjects experiencing treatment related serious adverse events (SAEs)	The primary endpoint is as assessed by the number of subjects with serious adverse events (SAEs) graded per NCI CTCAE v5.0.	From the time of informed consent through 90 days following termination of treatment with investigational product
Primary	The number of subjects experiencing dose-limiting toxicities (DLTs)	The primary endpoint is as assessed by the number of subjects experiencing dose limiting toxicities (DLTs) as defined by the protocol.	Up to 21 days following the first dose
Primary	The number of subjects experiencing abnormal laboratory evaluations	The primary endpoint is as assessed as the number of subjects experiencing changes in laboratory parameters from baseline.	From the time of informed consent through 90 days following termination of treatment with investigational product
Primary	The number of subjects experiencing changes from baseline in vital signs reported as adverse events	The primary endpoint is as assessed by the number of subjects experiencing clinically significant changes in vital signs from baseline.	From the time of informed consent through 90 days following termination of treatment with investigational product
Primary	The number of subjects experiencing abnormal electrocardiograms (ECG) reported as Adverse Events	The primary endpoint is as assessed by the the number of subjects experiencing clinically significant changes in ECG parameters from baseline.	From the time of informed consent through 90 days following termination of treatment with investigational product
Secondary	Preliminary anti-tumor activitiy of MEDI5752 using Objective Response based on RECIST v1.1	The endpoints for assessment of antitumor activity is defined by using ORR, PFS, BOR,DCR, DoR and TTR according to RECIST v1.1.	From the first dose of study drug through the date of documented progression, end of study, or date of death until study completion assessed up to 16 months.
Secondary	Pharmacokinetics of MEDI5752	The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. (e.g., Maximum plasma concentration[Cmax])	At Cycle1Day1, ,Cycle1Day2, Cycle1Day3, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle2Day8, Cycle3Day1, Cycle4Day1, Cycle5Day1, Cycle6Day1, Cycl7Day1, every 6 weeks after Cycle7Day1 (each cycle is 21 days) and up to 90 days following end of treatment.
Secondary	Immunogenicity of MEDI5752	The endpoints for the immunogenicity of MEDI5752 include the number of subjects who develop detectable anti-drug antibodies (ADAs)	At Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle2Day8, Cycle3Day1, Cycle4Day1, Cycle5Day1, Cycle6Day1, Cycl7Day1, every 6 weeks after Cycle7Day1 (each cycle is 21 days) and up to 90 days following end of treatment.
Secondary	PD-L1 Expression in subjects with advanced solid tumors	The endpoint for the PD-L1 expression will be determined by Immunohistochemistry characterization.	To be assessed at at baseline